雷替曲塞联合表柔比星经TACE治疗中晚期原发性肝癌的临床观察  

Clinical observation of raltitrexed combined with epirubicin in the treatment of primary liver cancer in middle and late stage by TACE

作　　者：余辉[1] 陈娟[1] YU Hui;CHEN Juan(Pharmacy Department of Fujian Cancer Hospital,Fuzhou 350014,China)

机构地区：[1]福建省肿瘤医院药剂科,福州市350014

出　　处：《临床合理用药杂志》2018年第23期7-8,21,共3页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的评价雷替曲塞联合表柔比星经TACE治疗中晚期原发性肝癌的临床效果。方法回顾性分析医院收治的88例不符合手术指征的原发性中晚期肝癌患者的临床资料,按不同治疗方案分为观察组与对照组,每组44例。观察2组患者近期(术后1个月)疗效,中位疾病进展时间及1年、2年生存率,患者血清AFP、CEA、转氨酶及胆红素以及不良反应发生情况。结果观察组术后1个月RR、DCR均高于对照组(P <0. 01);观察组的1年与2年生存率分别为83. 5%、56. 5%,高于对照组的64. 0%和36. 4%(P <0. 05);观察组中位生存期为11. 2个月,高于对照组的7. 1个月(P <0. 05);观察组术后1个月AFP、CEA、转氨酶、胆红素水平下降1/2的例数多于对照组(P <0. 05);2组间各不良反应发生率比较差异均无统计学意义(P> 0. 05)。结论雷替曲塞联合表柔比星经TACE治疗中晚期原发性肝癌的临床效果明显,用药安全性与患者耐受性均较好,值得临床推广应用。Objective To investigate the clinical effect of raltitrexed combined with epirubicin in the treatment of primary liver cancer in middle and late stage by TACE. Methods The clinical data of 88 patients with primary liver cancer in middle and late stage, who did not meet the operative conditions were analyzed retrospectively. The patients were divided into observation group and control group according to different treatment regimens, 54 cases in each group. To observe the effect of 1 months after the operation in two groups, the median time for disease progression, 1-year, 2-year survival rates, the levels of serum AFP, CEA, aminotransferase, bilirubin and the incidence of adverse reactions. Results RR and DCR in the observation group were significantly better than those in the control group 1 months after operation （P 〈 0.01 ）. The 1-and 2-year survival rates in the observation group were 83.5% ,56.5%, significantly higher than those in the control group （64.0% and 36. 4% ） （P 〈 0.05 ）. The median survival time of the observation group was 11.2 months, which was higher than that of the control group for 7.1 months （P 〈 0.05）. 1 months after operation, the patients in the observation group, whose AFP, CEA, aminotransferase and bilirubin level decreased by 1/2, were more than those in the control group （P 〈 0. 05 ）. There was no significant difference in the incidence of adverse reactions between the 2 groups （P 〉 0.05）. Conclusion The clinical effect of raltitrexed combined with epirubicin in the treatment of primary liver cancer in middle and late stage by TACE is obvious. And the drug safety and patient tolerance were all good. It is worthy of clinical application.

关 键 词：雷替曲塞 表柔比星 原发性肝癌 肝动脉化疗栓塞 

分 类 号：R735.7[医药卫生—肿瘤]